SBRT2015

ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) • Cure takes precedence over deferral of death. • Direct endpoints such as survival and quality of life take precedence over surrogates such as progression-free survival or response rate. • Disease-free survival in curative disease is a more valid surrogate than progression-free survival or response rate in noncurative disease. • Interpretation of the evidence of benefit derived from surrogate outcomes (such as progression-free survival) may be influenced by secondary outcome data.

Cherny NI, Ann Oncol 2015